Dermisonics Stock Performance
| DMSI Stock | USD 0.00003 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which means not very significant fluctuations relative to the market. the returns on MARKET and Dermisonics are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Dermisonics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite fairly uncertain basic indicators, Dermisonics demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 3:2 | Last Split Date 2005-01-19 |
Dermisonics | Build AI portfolio with Dermisonics Stock |
Dermisonics Relative Risk vs. Return Landscape
If you would invest 0.00 in Dermisonics on December 2, 2025 and sell it today you would earn a total of 0.00 from holding Dermisonics or generate 9.223372036854776E16% return on investment over 90 days. Dermisonics is currently generating 16.3934% in daily expected returns and assumes 128.0369% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Dermisonics, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Dermisonics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Dermisonics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Dermisonics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Dermisonics is way too risky over 90 days horizon | |
| Dermisonics has some characteristics of a very speculative penny stock | |
| Dermisonics appears to be risky and price may revert if volatility continues | |
| Dermisonics currently holds 2.56 M in liabilities. Dermisonics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Dermisonics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (5.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermisonics currently holds about 22.77 K in cash with (1.3 M) of positive cash flow from operations. | |
| Dermisonics has a frail financial position based on the latest SEC disclosures |
Dermisonics Fundamentals Growth
Dermisonics Stock prices reflect investors' perceptions of the future prospects and financial health of Dermisonics, and Dermisonics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dermisonics Stock performance.
| Return On Equity | -3.92 | ||||
| Return On Asset | -0.12 | ||||
| Current Valuation | 63.91 K | ||||
| Shares Outstanding | 63.91 M | ||||
| Price To Earning | (0.02) X | ||||
| Net Income | (5.08 M) | ||||
| Cash And Equivalents | 22.77 K | ||||
| Total Debt | 2.56 M | ||||
| Current Ratio | 0.01 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (1.3 M) | ||||
| Earnings Per Share | (0.44) X | ||||
| Market Capitalization | 1.92 K | ||||
| Total Asset | 20.08 M | ||||
| Retained Earnings | (16.49 M) | ||||
| Working Capital | (1.96 M) | ||||
| Current Asset | 27 K | ||||
| Current Liabilities | 1.98 M | ||||
About Dermisonics Performance
By evaluating Dermisonics' fundamental ratios, stakeholders can gain valuable insights into Dermisonics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Dermisonics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dermisonics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (7.32) | (7.69) | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.29) | (0.31) |
Things to note about Dermisonics performance evaluation
Checking the ongoing alerts about Dermisonics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dermisonics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dermisonics is way too risky over 90 days horizon | |
| Dermisonics has some characteristics of a very speculative penny stock | |
| Dermisonics appears to be risky and price may revert if volatility continues | |
| Dermisonics currently holds 2.56 M in liabilities. Dermisonics has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Dermisonics' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (5.08 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermisonics currently holds about 22.77 K in cash with (1.3 M) of positive cash flow from operations. | |
| Dermisonics has a frail financial position based on the latest SEC disclosures |
- Analyzing Dermisonics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dermisonics' stock is overvalued or undervalued compared to its peers.
- Examining Dermisonics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dermisonics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dermisonics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dermisonics' stock. These opinions can provide insight into Dermisonics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Dermisonics Stock analysis
When running Dermisonics' price analysis, check to measure Dermisonics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermisonics is operating at the current time. Most of Dermisonics' value examination focuses on studying past and present price action to predict the probability of Dermisonics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermisonics' price. Additionally, you may evaluate how the addition of Dermisonics to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |